A phase II study of AZD2171 in metastatic androgen independent prostate cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Jun 2015
At a glance
- Drugs Cediranib (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 09 Jan 2012 Planned end date changed from 1 Dec 2011 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 30 Jun 2010 Planned end date changed from 1 Aug 2008 to 1 Dec 2011 s reported by ClinicalTrials.gov.